ACIU
AC Immune SA
stockNASDAQ
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer's disease (ad). the company's pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.23 | 2026-11-06 | -5.61% | 5.029 |
| 1M | 2.40 | 2026-10-13 | -12.29% | 2.391 |
| 3M | 2.57 | 2026-08-13 | -18.09% | 1.801 |
| 6M | 2.84 | 2026-05-13 | -25.88% | 1.389 |
| 1Y | 3.23 | 2025-11-13 | -34.83% | 1.655 |
| 2Y | 3.13 | 2024-11-13 | -32.75% | — |
| 5Y | 5.90 | 2021-11-12 | -64.32% | 1.118 |
AC Immune SA (NASDAQ:ACIU) stock price today is $2.11, and today's volume is 79,229. ACIU is down 1.636% today. The 30 day average volume is 209,629. ACIU market cap is $209.29M with 99.43M shares outstanding.